Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

EXEL – Exelixis, Inc.

Exelixis, Inc.
EXEL
$37.26
Name : Exelixis, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $10,030,503,936.00
EPSttm : 2.08
finviz dynamic chart for EXEL
Exelixis, Inc.
$37.26
2.87%
$1.04

Float Short %

7.01

Margin Of Safety %

61

Put/Call OI Ratio

0.37

EPS Next Q Diff

EPS Last/This Y

0.91

EPS This/Next Y

0.5

Price

37.26

Target Price

45.11

Analyst Recom

1.95

Performance Q

-4.19

Relative Volume

1.59

Beta

0.29

Ticker: EXEL




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04EXEL46.150.720.0344753
2025-07-07EXEL44.150.610.1049517
2025-07-08EXEL43.510.610.1950488
2025-07-09EXEL44.060.600.1650741
2025-07-10EXEL45.150.600.5150924
2025-07-11EXEL44.880.600.6251267
2025-07-14EXEL45.560.600.2651254
2025-07-15EXEL44.060.601.6551407
2025-07-16EXEL44.810.620.0351925
2025-07-17EXEL44.890.620.4851933
2025-07-18EXEL44.470.620.8252217
2025-07-21EXEL44.260.690.1847275
2025-07-22EXEL44.490.690.1747737
2025-07-23EXEL45.410.680.0147999
2025-07-24EXEL44.810.400.0467975
2025-07-25EXEL45.60.350.2575155
2025-07-28EXEL44.420.350.2276101
2025-07-29EXEL36.970.350.2780054
2025-07-30EXEL36.850.350.1980300
2025-07-31EXEL36.230.352.6681431
2025-08-01EXEL37.260.370.5782398
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04EXEL46.15-24.7-29.12.61
2025-07-07EXEL44.15-24.7-97.72.61
2025-07-08EXEL43.51-24.7-74.72.61
2025-07-09EXEL44.07-24.7-52.32.61
2025-07-10EXEL45.17-24.7-42.52.61
2025-07-11EXEL44.86-24.7-48.22.61
2025-07-14EXEL45.58-24.7-49.12.61
2025-07-15EXEL44.06-24.7-89.02.61
2025-07-16EXEL44.81-24.7-48.42.61
2025-07-17EXEL44.87-24.7-61.02.61
2025-07-18EXEL44.48-24.7-69.12.61
2025-07-21EXEL44.26-24.7-65.92.61
2025-07-22EXEL44.47-24.7-58.32.61
2025-07-23EXEL45.40-24.7-45.22.61
2025-07-24EXEL44.79-24.2-73.02.61
2025-07-25EXEL45.60-24.2-47.52.61
2025-07-28EXEL44.30-24.2-85.12.61
2025-07-29EXEL36.94-23.4-197.92.62
2025-07-30EXEL36.8543.4-1.22.62
2025-07-31EXEL36.2245.5-13.12.71
2025-08-01EXEL37.2645.587.22.71
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04EXEL-7.960.657.72
2025-07-07EXEL-7.960.667.72
2025-07-08EXEL-7.960.667.72
2025-07-09EXEL-7.960.667.72
2025-07-10EXEL-7.960.667.72
2025-07-11EXEL-7.960.667.34
2025-07-14EXEL-7.960.877.34
2025-07-15EXEL-7.960.877.34
2025-07-16EXEL-7.960.877.34
2025-07-17EXEL-7.960.877.34
2025-07-18EXEL-8.030.877.34
2025-07-21EXEL-8.030.577.34
2025-07-22EXEL-8.030.577.34
2025-07-23EXEL-8.030.577.34
2025-07-24EXEL-8.030.577.34
2025-07-25EXEL-8.030.576.92
2025-07-28EXEL-8.030.596.92
2025-07-29EXEL-8.030.596.92
2025-07-30EXEL-8.030.596.92
2025-07-31EXEL-8.130.597.01
2025-08-01EXEL-8.130.597.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

0.68

Avg. EPS Est. Next Quarter

0.65

Insider Transactions

-8.13

Institutional Transactions

0.59

Beta

0.29

Average Sales Estimate Current Quarter

590

Average Sales Estimate Next Quarter

608

Fair Value

60.17

Quality Score

91

Growth Score

99

Sentiment Score

50

Actual DrawDown %

24.9

Max Drawdown 5-Year %

-44.5

Target Price

45.11

P/E

17.87

Forward P/E

11.57

PEG

0.54

P/S

4.5

P/B

4.95

P/Free Cash Flow

13.3

EPS

2.08

Average EPS Est. Cur. Y​

2.71

EPS Next Y. (Est.)

3.21

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

27.01

Relative Volume

1.59

Return on Equity vs Sector %

5.9

Return on Equity vs Industry %

24.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.1

EBIT Estimation

87.2
Exelixis, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 1147
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
stock quote shares EXEL – Exelixis, Inc. Stock Price stock today
news today EXEL – Exelixis, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EXEL – Exelixis, Inc. yahoo finance google finance
stock history EXEL – Exelixis, Inc. invest stock market
stock prices EXEL premarket after hours
ticker EXEL fair value insiders trading